Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
Psoriasis: Targets and Therapy · 2025-06 · Volume 15 · 243-259
DOI: 10.2147/ptt.s526748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psoriasis: Targets and Therapy, 2025-06. Verfasst von Ulrich Mrowietz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
- Dermatology Department, Polyclinic Courlancy-Bezannes, Reims, France.
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
- Dermatology Department, La Princesa University Hospital - Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
ORCID-Profile: Sascha Gerdes, Elke De Jong, Matthias Augustin
Zitieren
APA
Mrowietz, U., Sommer, R., Gerdes, S., Reguiai, Z., Weger, W., Daudén, E., Maul, J. T., Ghislain, P. D., Laws, P. M., Naldi, L., De Jong, E., Mburu, S., Koscielny, V., Massana, E., Domenech, A., Gaarn du Jardin, K., Kasujee, I., & Augustin, M. (2025). Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study. Psoriasis: Targets and Therapy, Volume 15, 243-259. https://doi.org/10.2147/ptt.s526748
Vancouver
Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, et al. Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study. Psoriasis: Targets and Therapy. 2025;Volume 15:243-259. doi:10.2147/ptt.s526748
BibTeX
@article{Mrowietz2025,
author = {Mrowietz, Ulrich and Sommer, Rachel and Gerdes, Sascha and Reguiai, Ziad and Weger, Wolfgang and Daudén, Esteban and Maul, Julia-Tatjana and Ghislain, Pierre-Dominique and Laws, Philip M and Naldi, Luigi and De Jong, Elke and Mburu, Sicily and Koscielny, Volker and Massana, Eric and Domenech, Arnau and Gaarn du Jardin, Kristian and Kasujee, Ismail and Augustin, Matthias},
title = {Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study},
journal = {Psoriasis: Targets and Therapy},
year = {2025},
volume = {Volume 15},
pages = {243--259},
doi = {10.2147/ptt.s526748}
}
EUVIMED